A new non-invasive method to assess cardiovascular risks in type 2 diabetic patients and the correlation to treatment types

Assessing the accumulation of advanced glycation end products among patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN50136555

Enrollment

180

Registered

2020-10-25

Start date

2019-12-01

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus

Interventions

AGEs (advanced glycation end-products) are measured using the non-invasive measurement of skin autofluorescence (SAF), which estimates the skin tissue AGEs content and thus may predict cardiovascular

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetic patients 2. Aged between 18 and 70 years 3. Moderate to high cardiovascular risk factors 4. Routinely attend the diabetes outpatients service of the Department of Internal Medicine in the Hospital of Melk 5. Patients will be included independently of their medication

Exclusion criteria

Exclusion criteria: Patients with dark skin, patients with skin diseases and the use of skin creams, such as agents used to “tan” or “brown” the skin, cannot be included in the study because of limitations to the autofluorescence measurement, which is adjusted to healthy white skin and may give inadequate results in dark skin.

Design outcomes

Primary

Measure	Time frame
AGEs accumulation measured using skin autofluorescence at 3, 6 and 12 months	—

Secondary

Measure	Time frame
The effect of various treatment types of type 2 diabetes on the accumulation of AGEs measured using skin autofluorescence at 3, 6 and 12 months	—

Countries

Austria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026